Analysts expect MEDNAX, Inc. (NYSE:MD) to post $436.56 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for MEDNAX’s earnings, with the highest sales estimate coming in at $463.30 million and the lowest estimate coming in at $420.79 million. MEDNAX reported sales of $845.92 million in the same quarter last year, which would suggest a negative year over year growth rate of 48.4%. The company is expected to issue its next earnings results before the market opens on Friday, May 7th.
On average, analysts expect that MEDNAX will report full-year sales of $1.80 billion for the current year, with estimates ranging from $1.73 billion to $1.88 billion. For the next fiscal year, analysts anticipate that the firm will post sales of $1.87 billion, with estimates ranging from $1.81 billion to $1.94 billion. Zacks Investment Research’s sales averages are a mean average based on a survey of analysts that that provide coverage for MEDNAX.
MEDNAX (NYSE:MD) last released its earnings results on Thursday, February 18th. The company reported $0.25 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.26 by ($0.01). MEDNAX had a negative net margin of 26.57% and a positive return on equity of 12.27%. The company had revenue of $416.63 million during the quarter, compared to analysts’ expectations of $456.01 million.
In related news, Director Roger Md Medel sold 100,000 shares of the stock in a transaction dated Thursday, April 1st. The shares were sold at an average price of $25.40, for a total value of $2,540,000.00. Following the completion of the transaction, the director now owns 1,318,439 shares in the company, valued at approximately $33,488,350.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 3.70% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Oregon Public Employees Retirement Fund lifted its holdings in MEDNAX by 2.0% in the 1st quarter. Oregon Public Employees Retirement Fund now owns 35,062 shares of the company’s stock valued at $893,000 after acquiring an additional 700 shares during the last quarter. Great West Life Assurance Co. Can lifted its holdings in MEDNAX by 2.6% in the 3rd quarter. Great West Life Assurance Co. Can now owns 42,701 shares of the company’s stock valued at $695,000 after acquiring an additional 1,071 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in MEDNAX by 10.3% in the 4th quarter. Nisa Investment Advisors LLC now owns 11,800 shares of the company’s stock valued at $290,000 after acquiring an additional 1,100 shares during the last quarter. Vantage Consulting Group Inc acquired a new stake in MEDNAX in the 4th quarter valued at about $43,000. Finally, Paces Ferry Wealth Advisors LLC acquired a new stake in MEDNAX in the 3rd quarter valued at about $40,000. Hedge funds and other institutional investors own 95.74% of the company’s stock.
MD traded down $0.29 during trading on Thursday, hitting $26.18. 770,394 shares of the company’s stock were exchanged, compared to its average volume of 941,073. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 2.16. MEDNAX has a 1 year low of $11.62 and a 1 year high of $29.25. The stock has a 50 day moving average price of $26.34 and a 200 day moving average price of $23.25. The firm has a market cap of $2.26 billion, a P/E ratio of -3.02, a price-to-earnings-growth ratio of 1.70 and a beta of 2.09.
MEDNAX, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.
Recommended Story: Why Invest in Dividend Kings
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.